Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | HTR1A | P08908 | 3/20 | 0.67 |
| ▸ | GFER | P55789 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10257007 | 0.98 | HTR1A (0.68) | ALDH1A1KMT2AHTR1AGFERPOLB | |
| SCHEMBL13089321 | 0.90 | KDM4E (0.66) | ALDH1A1KMT2AHTR1A | |
| SCHEMBL14384788 | 0.90 | HTR1A (0.65) | ALDH1A1KMT2AHTR1AGFERPOLB | |
| SCHEMBL12123664 | 0.88 | HTR1A (0.64) | ALDH1A1KMT2AHTR1AGFERPOLB | |
| SCHEMBL12123652 | 0.87 | HTR1A (0.69) | ALDH1A1HTR1APOLBHPGD | |
| SCHEMBL12123921 | 0.86 | HTR1A (0.64) | ALDH1A1KMT2AHTR1AGFERPOLB | |
| SCHEMBL12123907 | 0.86 | HTR1A (0.64) | ALDH1A1KMT2AHTR1AGFERPOLB | |
| SCHEMBL12123765 | 0.86 | ALDH1A1 (0.69) | ALDH1A1KMT2AHTR1APOLBLMNA | |
| SCHEMBL12123920 | 0.86 | HTR1A (0.55) | ALDH1A1KMT2AHTR1AGFERPOLB | |
| SCHEMBL12123759 | 0.85 | HTR1A (0.60) | ALDH1A1KMT2AHTR1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PHARMACYCLICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PHARMACYCLICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PHARMACYCLICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2865381-A1 | ITK inhibitors for treating blood cell malignancies | Pharmacyclics, Inc. (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2865381-A1 | ITK inhibitors for treating blood cell malignancies | Pharmacyclics, Inc. (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-8604031-B2 | Intracellular kinase inhibitors | MANNKIND CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-20110281850-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281850-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281850-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | MANNKIND CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | MANNKIND CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | MANNKIND CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293499-A1 | Intracellular Kinase Inhibitors | PI4KB, BTK, LTK | ALDH1A1 4370/4885KMT2A 1458/4885HTR1A 4740/4885 |
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | ALDH1A1 4370/4885KMT2A 1458/4885HTR1A 4740/4885 |
| US-20110281850-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | ALDH1A1 4370/4885KMT2A 1458/4885HTR1A 4740/4885 |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | ALDH1A1 4370/4885KMT2A 1458/4885HTR1A 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.